NCT05413655View on ClinicalTrials.gov

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

February 28, 2027

Conditions
Alzheimer Disease
Interventions
DRUG

EX039

The dosage form of EX039 is the capsule for oral use

DRUG

Placebo

The dosage form of Placebo is the capsule for oral use

Trial Locations (1)

100

RECRUITING

National Taiwan University Hospital, Taipei

Sponsors

Lead Sponsor

Excelsior
All Listed Sponsors
collaborator

Formosa Biomedical Technology Corp.

UNKNOWN

lead

Excelsior

INDUSTRY